National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 43858 [2024-10992]
Download as PDF
<![CDATA[
43858
Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Notices
(e.g., growth promotion, feed efficiency),
and effects on the animal microbiome.
We specifically asked for feedback on
how we could modernize or improve
PPM 1240.3605, what challenges were
presented by this PPM, and what
additional types of claims or ingredients
CVM should consider during its review
of the policy. Many stakeholders
requested that we update our PPM to
provide for a larger set of ingredients
that can be safely used in animal food
to be treated other than as drugs and to
encourage innovation that supports
human and animal health, promotes
sustainable animal production, and
provides benefits to the environment.
After a thorough review of PPM
1240.3605, and careful consideration of
stakeholder feedback, FDA has
determined that PPM 1240.3605 no
longer reflects Agency current thinking
and is therefore withdrawing the PPM.
FDA encourages firms developing
animal food, nutritional ingredients, or
non-nutritive ingredients with intended
uses that could make them a drug,
including substances that are for use in
animal food and are intended to affect
the structure or any function of the
animal’s body, to contact the Agency
early in the product development
process. To contact FDA’s Center for
Veterinary Medicine about an animal
food substance intended to have the
effects described above, please email
animalfood-premarket@fda.hhs.gov.
FDA intends to issue guidance to
clarify our current thinking on the
regulation of certain substances that are
for use in animal food and are intended
to affect the structure or any function of
an animal’s body.
Dated: May 14, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
19:14 May 17, 2024
Jkt 262001
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RFA–DK–23–004
Human Islet Research Network—Consortium
on Modeling Autoimmune Diabetes (UG3/
UH3).
Date: June 26, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Tori Stone, Ph.D.,
Scientific Review Officer, National Institutes
of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, MD
20892, (301) 827–0994, tori.stone@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10992 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
[FR Doc. 2024–10936 Filed 5–17–24; 8:45 am]
VerDate Sep<11>2014
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of K99/R00 Applications.
Date: June 24–25, 2024.
Time: 10:00 a.m. to 6:00 p.m.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Tracy Koretsky, Ph.D.,
Scientific Review Officer, National Institute
of General Medical Sciences, National
Institutes of Health, 45 Center Drive, MSC
6200, Room 3AN12F, Bethesda, Maryland
20892, 301–594–2886, tracy.koretsky@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10988 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Health Promotion in Communities Study
Section.
Date: June 10–11, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Ave. NW, Washington, DC 20037 (In-Person
Meeting).
Contact Person: Helena Eryam Dagadu,
MPH, Ph.D., Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3137,
Bethesda, MD 20892, (301) 435–1266,
dagaduhe@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Community Influences on Health Behavior
Study Section.
Date: June 11–12, 2024.
E:\FR\FM\20MYN1.SGM
20MYN1
]]>Agencies
[Federal Register Volume 89, Number 98 (Monday, May 20, 2024)]
[Notices]
[Page 43858]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10992]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; RFA-DK-23-004 Human
Islet Research Network--Consortium on Modeling Autoimmune Diabetes
(UG3/UH3).
Date: June 26, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NIDDK, Democracy II, Suite
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Tori Stone, Ph.D., Scientific Review Officer,
National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, MD 20892, (301) 827-0994,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-10992 Filed 5-17-24; 8:45 am]
BILLING CODE 4140-01-P
